Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

Author(s):
Jochems, A.; Leeneman, B.; Franken, M.G.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Eertwegh, A.J.M. van den; Groenewegen, G.; Groot, J.W.B. de; Haanen, J.B.A.G.; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.H.; Kruit, W.H.J.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M.; Uyl-de Groot, C.A.; Hoeven, K.J.M. van der
Published
2018
Publication type
Article / Letter to editor
clinical practicedrug useimmune-related adverse eventsipilimumabmetastatic melanomaoverall survivalreal-world outcomes
Date issued
2018-07-31
Language
English
Is part of
Anti-Cancer Drugs (2018), Vol. 29, no. 6, p. 572-578
hdl
1887/96179
doi
10.1097/CAD.0000000000000629